As Biotechnology businesses, Catalyst Biosciences Inc. (NASDAQ:CBIO) and Halozyme Therapeutics Inc. (NASDAQ:HALO), are affected by contrast. This especially applies to their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Catalyst Biosciences Inc.||8||0.00||N/A||-3.36||0.00|
|Halozyme Therapeutics Inc.||16||13.31||N/A||-0.36||0.00|
Table 1 shows the gross revenue, earnings per share and valuation for Catalyst Biosciences Inc. and Halozyme Therapeutics Inc.
Table 2 shows us the return on equity, net margins and return on assets of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Catalyst Biosciences Inc.||0.00%||-32.6%||-31.5%|
|Halozyme Therapeutics Inc.||0.00%||-20.4%||-11.4%|
Volatility and Risk
Catalyst Biosciences Inc. has a 1.88 beta, while its volatility is 88.00% which is more volatile than S&P 500. Halozyme Therapeutics Inc. on the other hand, has 1.75 beta which makes it 75.00% more volatile compared to S&P 500.
Catalyst Biosciences Inc.’s Current Ratio and Quick Ratio are 24.9 and 24.9 respectively. The Current Ratio and Quick Ratio of its competitor Halozyme Therapeutics Inc. are 2.9 and 2.7 respectively. Catalyst Biosciences Inc. therefore has a better chance of paying off short and long-term obligations compared to Halozyme Therapeutics Inc.
Insider and Institutional Ownership
The shares of both Catalyst Biosciences Inc. and Halozyme Therapeutics Inc. are owned by institutional investors at 82.9% and 86.6% respectively. Insiders held roughly 0.4% of Catalyst Biosciences Inc.’s shares. Competitively, Halozyme Therapeutics Inc. has 1% of it’s share held by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Catalyst Biosciences Inc.||-1.92%||10.38%||-5.43%||-4.21%||-15.39%||3.8%|
|Halozyme Therapeutics Inc.||1.92%||-3.3%||5.07%||6.19%||-1.34%||16.13%|
For the past year Catalyst Biosciences Inc.’s stock price has smaller growth than Halozyme Therapeutics Inc.
On 6 of the 7 factors Halozyme Therapeutics Inc. beats Catalyst Biosciences Inc.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; and Genentech. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.